I am a neuroscientist- neuropharmacologist determining molecular, cellular, synaptic and behavioural mechanisms of opioid addiction and persistent pain states.
Development Of A Novel Orally Active Peptide For The Treatment Of Pain
Funder
National Health and Medical Research Council
Funding Amount
$402,145.00
Summary
Chronic pain from damage to the nervous system is difficult to treat. A new type of drug has recently been developed from sea snail venom to treat chronic pain but is given by injection, which limits its use. Our research has developed a stable molecule that has analgesic activity when ingested. This proposal focuses on further testing to fully establish this molecule's therapeutic potential. This information can then attract a commercial partner to bring the new drug into general use.
Chronic pain affects 1 in 5 Australians and neuropathic pain is among the most severe forms of chronic pain. Several peptides derived from cone snail venoms have attracted recent attention as potential therapeutic agents for the treatment of neuropathic pain. One of these, conotoxin MVIIA, has recently been approved in the US and Europe and others, including CVID and ACVI, are in various stages of clinical investigation. These small disulfide rich peptides share the attractive features of peptid ....Chronic pain affects 1 in 5 Australians and neuropathic pain is among the most severe forms of chronic pain. Several peptides derived from cone snail venoms have attracted recent attention as potential therapeutic agents for the treatment of neuropathic pain. One of these, conotoxin MVIIA, has recently been approved in the US and Europe and others, including CVID and ACVI, are in various stages of clinical investigation. These small disulfide rich peptides share the attractive features of peptides in general of having exquisite selectivity for particular receptors, but also share the general disadvantages of peptides of short biological half-lives and poor bioavailablility. Stabilisation of these conotoxins has the potential to substantially increase their therapeutic potential. In preliminary studies we have shown that by introducing a circular petide backbone into a conotoxin using a linker sequence we can increase its stability and resistance to enzymatic degradation. We therefore propose that it will be possible to cyclise a wide range of conotoxin molecules and thereby improve their drug like properties. In this project we will use our cyclisation approach to develop new potential treatments for pain from two classes of conotoxins. One of the lead molecules shows oral bioavailability in an animal pain model and potentially represents a major breakthrough in the field of peptide drug delivery.Read moreRead less
New Peptide-based Drugs For The Treatment Of Neuropathic Pain
Funder
National Health and Medical Research Council
Funding Amount
$527,171.00
Summary
Chronic pain affects 1 in 5 Australians and neuropathic pain is among the most severe forms of chronic pain. Peptides from cone snail venoms have attracted recent attention as potential therapeutic agents for the treatment of neuropathic pain. Unfortunately, these peptides suffer from the disadvantage of short biological half-lives and poor activity when taken orally. We have developed a new approach to solve these problems that we will apply to develop new drugs for the treatment of pain.
Increasing The Capacity Of Community Pharmacy For Screening, Brief Intervention And Referral For Treatment Of Pharmaceutical Opioid Use Disorders
Funder
National Health and Medical Research Council
Funding Amount
$177,197.00
Summary
Pharmaceutical opioid dependence is a growing problem. There are effective treatments available, yet few people who need treatment receive it. Currently, pharmacists receive little training on substance use disorders, yet are in contact with almost every person likely to develop problems with pharmaceutical opioids. This project will take an innovative approach to involve pharmacists in identifying those developing problems with pharmaceutical opioids and referring them to treatment.
The Analgesic Evaluation Of Novel Natural Products From The Australian Plant Barringtonia Acutangula
Funder
National Health and Medical Research Council
Funding Amount
$174,500.00
Summary
This project aims to evaluate the analgesic activity of several novel natural products that have been isolated from the Australian plant Barringtonia acutangula. An Australian Aboriginal tribe have been known to use B. acutangula aqueous bark extracts for its analgesic properties. Griffith University researchers have confirmed this biological activity in the crude aqueous bark extract. A large scale extraction and isolation process will obtain the novel compounds in sufficient quantities that wi ....This project aims to evaluate the analgesic activity of several novel natural products that have been isolated from the Australian plant Barringtonia acutangula. An Australian Aboriginal tribe have been known to use B. acutangula aqueous bark extracts for its analgesic properties. Griffith University researchers have confirmed this biological activity in the crude aqueous bark extract. A large scale extraction and isolation process will obtain the novel compounds in sufficient quantities that will allow for their pharmacological evaluation as potential analgesic drugs.Read moreRead less
Reduction Of Chronic Post-surgical Pain With Ketamine - ROCKet Study
Funder
National Health and Medical Research Council
Funding Amount
$4,823,395.00
Summary
Chronic post-surgical pain (CPSP) is a common complication of major surgery, and a significant burden on quality of life and ongoing health costs. Ketamine is a drug used by anaesthetists to treat severe acute surgical pain. Various small studies suggest that it may be unique in its ability to reduce the risk of CPSP. We propose a large trial of ketamine during & after anaesthesia for major surgery to test this. Demonstration of effectiveness would promote widespread change in clinical practice.
There is huge interest in the development of bioactive peptides and proteins for the treatment of a wide range of diseases. However, the biggest challenge in the development of peptide and protein drugs is overcoming their poor stability in the human body. The aim of my research is to develop novel methods that provide therapeutically promising peptides and proteins the ability to resist the body’s natural degradation pathways so they can reach their biological target and act as effective drugs.
Novel Prolonged-release Polymeric Microparticles For Relief Of Intractable Cancer-related Pain
Funder
National Health and Medical Research Council
Funding Amount
$796,950.00
Summary
For the 10-30% of patients with advanced cancer who experience intractable pain despite administration of large doses of morphine-like drugs by mouth or injection, more invasive dosing routes may be needed. This project will utilise innovative polymer chemistry to develop bioerodable prolonged-release polymer microparticles to deliver pain-killers into the spinal fluid near to the cells that mediate their actions, with a view to producing prolonged periods of analgesia in these patients.
ENDOGENOUS PAIN RELIEF IN HEALTHY AND OSTEOARTHRITIC PATIENTS
Funder
National Health and Medical Research Council
Funding Amount
$509,926.00
Summary
Pain has a detrimental impact on ones quality of life and a significant financial impact on the community. Given this, there is a substantial effort aimed at developing pain relieving compounds. One way in which our own brain can provide complete pain relief is via a mechanism called diffuse noxious inhibitory control. We currently do not know how this mechanism works and the aim of this investigation is to explore this mechanism in healthy and osteoarthritis patients use human brain imaging.